Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

View Full Paper
Ask AI
Bookmark
Share

Authors

NJNitin JainLMLucia MasárováSKSteven Kornblau

Discussion

Loading...

Member takes

Overview

Randomized Phase II trial reduced grade ≥3 neutropenia and infections in treatment-naive CLL, suggesting later addition of obinutuzumab may enhance safety.

Key Points

  • AV triplet therapy achieved BM uMRD4 rates of 90% at C26, indicating its effectiveness for treatment-naive CLL.
  • Grade ≥3 neutropenia significantly higher in AV + early O arm with 64% occurrence in the first year.
  • Adverse events were recorded using Fisher's Exact Test, highlighting the comparative safety profile of therapy timing.
  • Results imply that later addition of obinutuzumab improves tolerability while maintaining efficacy against CLL.

Cite This Study

Jain et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d755https://doi.org/10.1182/blood-2025-681
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)2025 · 8 citations
  2. 2Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease (BruVenG).2025
  3. 3Mutation-guided finite-duration acalabrutinib plus venetoclax for relapse after first-line finite-duration COVALENT Bruton tyrosine kinase inhibitor plus venetoclax‒based combination therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: Phase 2 MAVRiC study2025
  4. 4Long term follow-up and results of retreatement after obinutuzumab-venetoclax in first-line CLL patients with coexisting conditions2025
  5. 5A Phase II trial of obinutuzumab, ibrutinib and venetoclax in patients with previously untreated follicular lymphoma; A University of California hematologic malignancies consortium study2025